Tagged with M

CAEMe Through your work as member of the Council of the IFPMA, as well as FIFARMA, and CAEMe, you must have a very developed and unique perspective on the characteristics of the Argentinean and International pharmaceutical markets. Can you explain the importance of Argentina within the Latin American framework? One important…

Medy-Tox What drove you to make the move from the academia to the business sector when you decided to establish Medy-Tox in 2000? I founded Medy-tox in the year 2000, in the context of a very difficult economic moment for Korea which was facing strong financial restrictions on government spending imposed…

Ministry of Health & Welfare Italy Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009 onwards to foster maximum quality and equality in health for all citizens, highlighting those concerning preventive Health? The current government…

Minister for Health How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the national health insurance system in 1977, the Korean national healthcare system has been experiencing dramatic growth, guaranteeing healthcare to every…

Gilead Sciences Germany Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in products such as Tamiflu, Viread and Atripla. What would you highlight as the main achievements of the company in the…

TEVA Germany The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process continued with the recent acquisition of AWD Pharma in 2008. What as the impact of such acquisitions in your German…

Boehringer Ingelheim Indonesia After 20 years experience with Boehringer Ingelheim, what would you say are the main specificities of the Indonesian pharmaceutical industry? Indonesia differs some what from other Asian countries, starting from being a non reimbursement market with a very large population, to people having a small disposable income. Indonesia also has…

Astellas Pharma Germany Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the two companies. Could you describe their integration process in Germany and which were the main synergies in the local market?…

Boryung Pharmaceutical Boryung has a very interesting history, starting as a pharmacy in Seoul and going on to become one of the top 10 pharmaceutical companies in South Korea. What can you tell us, as the founder, about this notable achievement? Boryung just celebrated in 2007 its 50th anniversary, since it was…